1.Eosinophilia due to osteomyelitis in a dog.
Seifollah N DEHGHANI ; Shahin HAJIGHAHRAMANI
Journal of Veterinary Science 2005;6(3):255-257
A dog with a lesion in the left elbow area and presence of purulent materials was referred to hospital;history, clinical examination, laboratory test and radiological evaluation of the dog proved the presence of osteomyelitis. Eosinophilia was evident by haematologic test. Intensive antibiotic, anti-inflammatory medication, local wound management and restricted physical activity, improved osteomelitis condition and reduced eosinophil number. Therefore it seemed that osteomyelitis was the cause of eosinophilia in this dog.
Animals
;
Dog Diseases/*blood/therapy
;
Dogs
;
Eosinophilia/etiology/*veterinary
;
Male
;
Osteomyelitis/complications/*veterinary
2.Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.
Wook Hun CHUNG ; Seon Ah PARK ; Jae Hoon LEE ; Dai Jung CHUNG ; Wo Jong YANG ; Eun Hee KANG ; Chi Bong CHOI ; Hwa Seok CHANG ; Dae Hyun KIM ; Soo Han HWANG ; Hoon HAN ; Hwi Yool KIM
Journal of Veterinary Science 2013;14(4):495-497
The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.
Animals
;
Cartilage Diseases/etiology/therapy/*veterinary
;
*Cord Blood Stem Cell Transplantation/veterinary
;
Dog Diseases/etiology/*therapy
;
Dogs
;
Embolism/etiology/therapy/*veterinary
;
Female
;
Humans
;
Mesenchymal Stromal Cells/cytology/*metabolism
;
Spinal Cord Diseases/etiology/therapy/*veterinary
;
Treatment Outcome
3.Retrieval of an embolization coil accidentally dislodged in the descending aorta of a dog with a patent ductus arteriosus.
Seung Gon LEE ; Changbaig HYUN
Journal of Veterinary Science 2007;8(2):205-207
A 3.5-year-old intact female miniature poodle (weighing 2.7 kg) was referred to the Veterinary Teaching Hospital at Kangwon National University, because of inadvertent aortic embolization, by an occlusion coil used for the closure of patent ductus arteriosus (PDA). The coil was found at the site of the branching renal arteries in the abdominal aorta. A foreign body forceps with a three-wire nail tip was used, with fluoroscopic guidance, to retrieve the coil. After the removal, the dog was treated with heparin to prevent thromboembolization.
Animals
;
*Aorta, Thoracic
;
Dog Diseases/*etiology/surgery
;
Dogs
;
Ductus Arteriosus, Patent/*therapy
;
Embolization, Therapeutic/*adverse effects/instrumentation
;
Female
;
Foreign Bodies/therapy/*veterinary
4.Use of aglepristone for the treatment of P4 induced insulin resistance in dogs.
Enrico BIGLIARDI ; Carla BRESCIANI ; Daniela CALLEGARI ; Francesco DI IANNI ; Giorgio MORINI ; Enrico PARMIGIANI ; Ezio BIANCHI
Journal of Veterinary Science 2014;15(2):267-271
Insulin resistance (IR) in dogs is suspected when hyperglycemia is present despite administration of insulin doses greater than 1.0 to 1.5 UI/kg. IR is caused by increases in counter regulatory hormones concentrations (glucagon, glucocorticoids, catecholamines and growth hormone). This study was conducted to investigate the use of aglepristone (RU 46534), a P4 receptor antagonist, for the treatment of IR diabetes mellitus in bitches during the luteal phase. All animals were treated with porcine insulin zinc suspension (Caninsulin) and aglepristone (Alizin) 10 mg/kg subcutaneously at day 1, 2, 9 and 17 from diagnosis. At day 5, no significant variation in glycemia was shown. At day 12 and 20, serum glucose concentrations were significant lower (p < 0.05). From day 12 the insulin dose was reduced to 0.8 IU BID. Insulin was reduced in the following weeks and glycemia was controlled.
Animals
;
Blood Glucose/analysis
;
Diabetes Mellitus/drug therapy/etiology/*veterinary
;
Dog Diseases/*drug therapy/etiology
;
Dogs
;
Estrenes/*therapeutic use
;
Estrous Cycle
;
Female
;
Hypoglycemic Agents/therapeutic use
;
Insulin Resistance
;
Pregnancy
;
Radioimmunoassay/veterinary
;
Receptors, Progesterone/*antagonists & inhibitors
5.A case of adrenal gland dependent hyperadrenocorticism with mitotane therapy in a Yorkshire terrier dog.
Young Mi LEE ; Byeong Teck KANG ; Dong in JUNG ; Chul PARK ; Ha Jung KIM ; Ju Won KIM ; Chae Young LIM ; Eun Hee PARK ; Hee Myung PARK
Journal of Veterinary Science 2005;6(4):363-366
Hyperadrenocorticism, a disorder characterized by excessive production of cortisol by the adrenal cortex, is wellrecognized in dogs. A 10-year-old, intact male, Yorkshire terrier dog was evaluated because of corneal ulceration and generalized alopecia. Diagnosis was made based on history taking, clinical signs, physical examination, and results of routine laboratory testing (complete blood count, serum biochemical analysis, and urinalysis). In addition, adrenocorticotropic hormone (ACTH) stimulation test and abdominal ultrasonography were also used to diagnose this case. The patient was diagnosed as adrenal gland neoplasia and medical therapy using the adrenocorticolytic agent, mitotane, was initiated. An ACTH stimulation test was performed after initial therapy. After successful induction was obtained, maintenance therapy with mitotane still continued.
Adrenal Gland Neoplasms/complications/diagnosis/drug therapy/*veterinary
;
Adrenocortical Hyperfunction/diagnosis/drug therapy/etiology/*veterinary
;
Adrenocorticotropic Hormone/blood
;
Animals
;
Antineoplastic Agents, Hormonal/*therapeutic use
;
Dog Diseases/*drug therapy
;
Dogs
;
Male
;
Mitotane/*therapeutic use
;
Radiography, Abdominal/veterinary
;
Tomography, X-Ray/veterinary
6.Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.
Ji Young JUNG ; Eui Hwa NAM ; Seol Hee PARK ; Seung Hee HAN ; Cheol Yong HWANG
Journal of Veterinary Science 2013;14(2):199-205
In humans, skin barrier dysfunction is thought to be responsible for enhanced penetration of allergens. Similar to conditions seen in humans, canine atopic dermatitis (CAD) is characterized by derangement of corneocytes and disorganization of intercellular lipids in the stratum corenum (SC) with decreased ceramide levels. This study was designed to evaluate the effects of a moisturizer containing ceramide on dogs with CAD. Dogs (n = 20, 3~8 years old) with mild to moderate clinical signs were recruited and applied a moisturizer containing ceramide for 4 weeks. Transepidermal water loss (TEWL), skin hydration, pruritus index for canine atopic dermatitis (PICAD) scores, and canine atopic dermatitis extent and severity index (CADESI) scores of all dogs were evaluated. Skin samples from five dogs were also examined with transmission electron microscopy (TEM) using ruthenium tetroxide. TEWL, PICAD, and CADESI values decreased (p < 0.05) and skin hydration increased dramatically over time (p < 0.05). Electron micrographs showed that the skin barrier of all five dogs was partially restored (p < 0.05). In conclusion, these results demonstrated that moisturizer containing ceramide was effective for treating skin barrier dysfunction and CAD symptoms.
Animals
;
Ceramides/*therapeutic use
;
Cholesterol/*therapeutic use
;
Dermatitis, Atopic/complications/drug therapy/physiopathology/*veterinary
;
Dog Diseases/*drug therapy/etiology/physiopathology
;
Dogs
;
Emollients/*therapeutic use
;
Epidermis/drug effects/physiopathology/ultrastructure
;
Fatty Acids, Nonesterified/*therapeutic use
;
Female
;
Male
;
Microscopy, Electron, Transmission/veterinary
;
Pruritus/drug therapy/etiology/physiopathology/veterinary
;
Republic of Korea
;
Ruthenium Compounds/chemistry
;
Water Loss, Insensible/drug effects